Connect your AI

AbCellera Biologics Inc. ABCL Net margin

Net margin at other companies

Twist Bioscience CorporationTWST

-19.8%-7.7pp

Recursion Pharmaceuticals, Inc.RXRX

-842.9%-92.4pp

AnaptysBio, Inc.ANAB

-49.9%-22.6pp

ZymeworksZYME

-126.3%+5.0pp

PrecigenPGEN

-3,656%—

ADMA BiologicsADMA

32.4%-12.6pp

Other financials

Income statement

Revenue$8.3M+96.3%

Operating income-$57.5M+8.2%

Net income-$43.2M+5.4%

EPS (diluted)-$0.14+6.7%

Balance sheet

Cash & equivalents$102.1M-44.6%

Total debt$140.2M+107%

Total equity$938.1M-8.3%

Total assets$1.3B-2.8%

Cash flow

Operating cash flow-$33.5M-190%

CapEx$3.8M-64.0%

Free cash flow-$37.4M-68.3%

Valuation

Market cap$1.72B+59.2%

Enterprise value$1.76B+100.0%

P/S21.7×-25.0×

Profitability

Operating margin-267.6%-120pp

FCF margin-238.9%-90.9pp

Returns & leverage

Return on equity-14.7%-0.8pp

Debt / equity0.1×+0.1×

Current ratio14.1×+3.9×

Where this comes from

Calculated from AbCellera Biologics Inc.’s reported figures.

net income/total revenue=-181.7%

Based on trailing twelve months.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s net margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AbCellera Biologics Inc.'s net margin?: AbCellera Biologics Inc. (ABCL) reported net margin of -181.7% in Q1 2026.
How has AbCellera Biologics Inc.'s net margin changed year-over-year?: AbCellera Biologics Inc.'s net margin increased by 75.0% year-over-year, from -726.2% to -181.7%.
What is the long-term trend for AbCellera Biologics Inc.'s net margin?: Over 4 years (2020 to 2025), AbCellera Biologics Inc.'s net margin has grown at a 39.8% compound annual growth rate (CAGR), from 51% to -194.9%.
What does net margin mean?: Net income as a percentage of revenue (trailing twelve months). The bottom-line profitability measure after all costs, interest, and taxes.